US Pharma MarketingKrazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12
FDA finalizes Krazati CRC withdrawal; Wegovy succeeds in kids 6-12; Structure releases obesity data; Cloverleaf Bio raises $33M; Windward Bio Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Plus news about Structure Therapeutics, Cloverleaf Bio and Windward Bio.
FDA finalizes Krazati withdrawal: Regulators officially finalized the drug’s withdrawal in second-line colorectal cancer last week. Krazati had
Source: Endpoints News